BP1001-A in Patients With Advanced or Recurrent Solid Tumors
Status:
Not yet recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This is a phase I, open-label, study of BP1001-A in participants with advanced or recurrent
solid tumors. The dose escalation phase will determine the safety and the maximum tolerated
dose (MTD) or maximum administered dose (MAD) of BP1001-A as a single agent. After the MTD or
MAD of BP1001-A is established, the dose expansion phase will commence and determine the
safety, toxicity and response of BP1001-A in combination with paclitaxel.